Inhibiting the biological crosstalk of autophagy and mitochondrial function underlying pancreatic ductal adenocarcinoma

by Thamarasee Jeewandara , Medical XpressAutophagy inhibition leads to a drop in the LIP in PDAC. (A) Autophagy was inhibited genetically or pharmacologically in PDAC cells, and the relative LIP was d

Updated on: February 24,2024

Inhibiting the biological crosstalk of autophagy and mitochondrial function underlying pancreatic ductal adenocarcinoma

by Thamarasee Jeewandara , Medical XpressAutophagy inhibition leads to a drop in the LIP in PDAC. (A) Autophagy was inhibited genetically or pharmacologically in PDAC cells, and the relative LIP was d

Updated on:February 24,2024

New study helps explain the anti-cancer properties of mannose sugar

bySanford Burnham Prebys Medical Discovery InstituteProposed model for the mechanism underlying anticancer activity of mannose in mannose phosphate isomerase knockout (MPI-KO) human cancer cells

Updated on: January 13,2024

New study helps explain the anti-cancer properties of mannose sugar

bySanford Burnham Prebys Medical Discovery InstituteProposed model for the mechanism underlying anticancer activity of mannose in mannose phosphate isomerase knockout (MPI-KO) human cancer cells

Updated on:January 13,2024

Computational method used to directly measure tumors shows hypertranscription is ubiquitous across cancers

by Bob Yirka , Medical XpressOverview of RNA output analysis with RNAmp. (A) Hypertranscription occurs when cancer cells elevate their RNA output above normal cell levels (left). Upon RNA extraction f

Updated on: February 20,2024

Computational method used to directly measure tumors shows hypertranscription is ubiquitous across cancers

by Bob Yirka , Medical XpressOverview of RNA output analysis with RNAmp. (A) Hypertranscription occurs when cancer cells elevate their RNA output above normal cell levels (left). Upon RNA extraction f

Updated on:February 20,2024

Drug developed for pancreatic cancer shows promise against most aggressive form of medulloblastoma

by Leslie Cantu,Medical University of South CarolinaGraphical abstract. Credit:Journal of Clinical Investigation(2024). DOI: 10.1172/JCI171136A drug that was developed to treat pancr

Updated on: August 27,2024

Drug developed for pancreatic cancer shows promise against most aggressive form of medulloblastoma

by Leslie Cantu,Medical University of South CarolinaGraphical abstract. Credit:Journal of Clinical Investigation(2024). DOI: 10.1172/JCI171136A drug that was developed to treat pancr

Updated on:August 27,2024

New model could reduce reliance on chemotherapy

byAnglia Ruskin UniversityCredit: Unsplash/CC0 Public DomainA model co-designed by a professor at Anglia Ruskin University is expected to reduce the need for chemotherapy in up to 38% of breast

Updated on: July 17,2024

New model could reduce reliance on chemotherapy

byAnglia Ruskin UniversityCredit: Unsplash/CC0 Public DomainA model co-designed by a professor at Anglia Ruskin University is expected to reduce the need for chemotherapy in up to 38% of breast

Updated on:July 17,2024

'Magic bullet' takes aim at pancreatic cancer

by University of South AustraliaAxial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domainEvery day, more than 1200 people worldwide are told they

Updated on: March 14,2024

'Magic bullet' takes aim at pancreatic cancer

by University of South AustraliaAxial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domainEvery day, more than 1200 people worldwide are told they

Updated on:March 14,2024

Renal impairment linked to worse prognosis in IgD multiple myeloma

by Elana GotkineFor patients with immunoglobulin D multiple myeloma (IgD MM), those with renal impairment (RI) have poorer prognosis and shorter median survival than those with no renal impairment (no

Updated on: January 04,2024

Renal impairment linked to worse prognosis in IgD multiple myeloma

by Elana GotkineFor patients with immunoglobulin D multiple myeloma (IgD MM), those with renal impairment (RI) have poorer prognosis and shorter median survival than those with no renal impairment (no

Updated on:January 04,2024

Adding MS drug to targeted cancer therapy may improve glioblastoma outcomes

by University of California - San DiegoIn a patient-derived tumor model in mice, glioblastoma tumors (dark purple) shrink significantly when treated with both the MS drug teriflunomide and the ta

Updated on: May 05,2024

Adding MS drug to targeted cancer therapy may improve glioblastoma outcomes

by University of California - San DiegoIn a patient-derived tumor model in mice, glioblastoma tumors (dark purple) shrink significantly when treated with both the MS drug teriflunomide and the ta

Updated on:May 05,2024

Identifying key markers in pancreatic cancer progression using a new analysis pipeline

byJohns Hopkins UniversityNovel computational pipeline developed by Johns Hopkins Kimmel Cancer Researchers to identify early molecular and cellular progression to pancreatic ductal adenocarcino

Updated on: September 10,2024

Identifying key markers in pancreatic cancer progression using a new analysis pipeline

byJohns Hopkins UniversityNovel computational pipeline developed by Johns Hopkins Kimmel Cancer Researchers to identify early molecular and cellular progression to pancreatic ductal adenocarcino

Updated on:September 10,2024

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

by Jeff Hansen,University of Alabama at BirminghamLudwine Messiaen, Ph.D., left, and Magdalena Koczkowska, Ph.D. Credit: University of Alabama at BirminghamInternational collaborative research l

Updated on: March 14,2024

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

by Jeff Hansen,University of Alabama at BirminghamLudwine Messiaen, Ph.D., left, and Magdalena Koczkowska, Ph.D. Credit: University of Alabama at BirminghamInternational collaborative research l

Updated on:March 14,2024

A new combination therapy regimen shows promising results for prostate cancer

by Huntsman Cancer InstituteCredit: CC0 Public DomainTALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progress

Updated on: January 28,2024

A new combination therapy regimen shows promising results for prostate cancer

by Huntsman Cancer InstituteCredit: CC0 Public DomainTALAPRO-2, a study led by Neeraj Agarwal, MD, demonstrated that using TALZENNA, in combination with XTANDI, may reduce the risk of disease progress

Updated on:January 28,2024

New tech addresses manufacturing bottlenecks for a lifesaving blood cancer treatment

byUniversity of South AustraliaSchematic of forces acting on cells in inertial microfluidics. Credit:Cytotherapy(2024). DOI: 10.1016/j.jcyt.2024.05.005Researchers from the University

Updated on: July 30,2024

New tech addresses manufacturing bottlenecks for a lifesaving blood cancer treatment

byUniversity of South AustraliaSchematic of forces acting on cells in inertial microfluidics. Credit:Cytotherapy(2024). DOI: 10.1016/j.jcyt.2024.05.005Researchers from the University

Updated on:July 30,2024